Company registration number 00450186 (England and Wales)
THE PAINSWICK PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
THE PAINSWICK PHARMACY LIMITED
COMPANY INFORMATION
Directors
A Kikic
P Kikic
Company number
00450186
Registered office
Nutgrove House
New Street
Painswick
Stroud
GL6 6XH
Accountants
M J Goldman (Chartered Accountants)
Hollinwood Business Centre
Albert Street
Oldham
Lancashire
OL8 3QL
Business address
New Street
Painswick
Stroud
Gloucestershire
GL6 6XH
THE PAINSWICK PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
THE PAINSWICK PHARMACY LIMITED
BALANCE SHEET
AS AT
31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
4,167
2,382
Current assets
Stocks
37,948
38,122
Debtors
4
433,687
418,266
Cash at bank and in hand
19,168
20,248
490,803
476,636
Creditors: amounts falling due within one year
5
(105,999)
(147,576)
Net current assets
384,804
329,060
Total assets less current liabilities
388,971
331,442
Creditors: amounts falling due after more than one year
6
(15,939)
(6,147)
Provisions for liabilities
(1,042)
(596)
Net assets
371,990
324,699
Capital and reserves
Called up share capital
7
5,000
5,000
Profit and loss reserves
366,990
319,699
Total equity
371,990
324,699

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 7 December 2025 and are signed on its behalf by:
A Kikic
Director
Company Registration No. 00450186
THE PAINSWICK PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
1
Accounting policies
Company information

The Painswick Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is New Street, Painswick, Stroud, Gloucestershire, GL6 6XH.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, except for modification

to a fair value basis where specified in the accounting policies below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

Revenue is derived from the provision of over the counter medicines, NHS prescription services and chemist goods. The revenue in respect to the sale of over the counter medicines and the sale of chemist items are recognised at the point where the goods have been sold and fully paid. Revenue from NHS prescription services are recognised as earned when, and the extent that, the company obtains the right to consideration in exchange for its performance and fulfilment of prescription services.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
25% Reducing balance
Fixtures and fittings
20% Reducing balance
Computers
25% Straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

THE PAINSWICK PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 3 -
1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Basic financial assets, which include debtors and cash, together with basic financial liabilities, including creditors, are initially recognised at transaction cost and not amortised as they are either receivable or payable within one year.

 

Creditors payable after one year constitutes a commercial business loan with a market rate of interest being applied. This is recognised in full.

 

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

THE PAINSWICK PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 4 -
1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
5
7
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2024
102,590
Additions
3,203
At 31 March 2025
105,793
Depreciation and impairment
At 1 April 2024
100,208
Depreciation charged in the year
1,418
At 31 March 2025
101,626
Carrying amount
At 31 March 2025
4,167
At 31 March 2024
2,382
THE PAINSWICK PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 5 -
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
57,841
71,215
Other debtors
375,846
347,051
433,687
418,266
5
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
16,803
14,723
Trade creditors
72,230
97,032
Taxation and social security
16,297
14,724
Other creditors
669
21,097
105,999
147,576
6
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
15,939
6,147
7
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
5,000
5,000
5,000
5,000
8
Financial commitments, guarantees and contingent liabilities

The company is a party to a cross-guarantee arrangement with its fellow group undertakings. Under this agreement, the company and other group companies have jointly and severally guaranteed the bank borrowings and other obligations of the group.

 

No liability has been recognised in respect to this guarantee, as the directors consider the likelihood of the guarantee being called to be remote.

 

The company has granted a fixed and floating charge over its assets as security for these facilities.

2025-03-312024-04-01falsefalsefalse08 December 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityA KikicP Kikic004501862024-04-012025-03-3100450186bus:Director12024-04-012025-03-3100450186bus:Director22024-04-012025-03-31004501862025-03-31004501862024-03-3100450186core:OtherPropertyPlantEquipment2025-03-3100450186core:OtherPropertyPlantEquipment2024-03-3100450186core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3100450186core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3100450186core:Non-currentFinancialInstrumentscore:AfterOneYear2025-03-3100450186core:Non-currentFinancialInstrumentscore:AfterOneYear2024-03-3100450186core:CurrentFinancialInstruments2025-03-3100450186core:CurrentFinancialInstruments2024-03-3100450186core:ShareCapital2025-03-3100450186core:ShareCapital2024-03-3100450186core:RetainedEarningsAccumulatedLosses2025-03-3100450186core:RetainedEarningsAccumulatedLosses2024-03-3100450186core:ShareCapitalOrdinaryShareClass12025-03-3100450186core:ShareCapitalOrdinaryShareClass12024-03-3100450186core:PlantMachinery2024-04-012025-03-3100450186core:FurnitureFittings2024-04-012025-03-3100450186core:ComputerEquipment2024-04-012025-03-31004501862023-04-012024-03-3100450186core:OtherPropertyPlantEquipment2024-03-3100450186core:OtherPropertyPlantEquipment2024-04-012025-03-3100450186core:WithinOneYear2025-03-3100450186core:WithinOneYear2024-03-3100450186core:Non-currentFinancialInstruments2025-03-3100450186core:Non-currentFinancialInstruments2024-03-3100450186bus:OrdinaryShareClass12024-04-012025-03-3100450186bus:OrdinaryShareClass12025-03-3100450186bus:OrdinaryShareClass12024-03-3100450186bus:PrivateLimitedCompanyLtd2024-04-012025-03-3100450186bus:FRS1022024-04-012025-03-3100450186bus:AuditExemptWithAccountantsReport2024-04-012025-03-3100450186bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3100450186bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP